Lymphoma Clinical Trials in Dallas

Showing 141-160 of 450 trials

Tempus Priority Study: A Pan-tumor Observational Study

NCT05179824

Observational study that will be collecting clinical and molecular health information from cancer patients who have received comprehensive genomic profiling and meet the specific eligibility criteria outlined for each cohort with the goal of conducting research to advance cancer care and create a dataset that furthers cancer research.

Breast CancerProstate CancerBladder Cancer+24 more

Tempus AI1,000 participantsStarted Oct 2020

Dallas, Texas, United States • Houston, Texas, United States

RECRUITINGPhase 2< 1 mile

DALY II USA/ MB-CART2019.1 for DLBCL

NCT04792489

DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory diffuse large B cell lymphoma (DLBCL) after receiving at least two lines of therapy. Additional cohorts include subjects with B-cell primary or secondary central nervous system (CNS) lymphoma (PCNSL) and (SCNSL), mantle cell lymphoma (MCL) and Richter's transformation (RT) after receiving at least one line of therapy.

Refractory Diffuse Large B Cell Lymphoma (DLBCL)Relapsed Diffuse Large B Cell LymphomaHigh Grade B-cell Lymphoma (HGBCL)+5 more

Miltenyi Biomedicine GmbH248 participantsStarted May 2021

Gilbert, Arizona, United States • Phoenix, Arizona, United States • La Jolla, California, United States +22 more locations

Tempus Priority Study: A Pan-tumor Observational Study

DALY II USA/ MB-CART2019.1 for DLBCL

Lymphoma Trials in Other Cities

Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.

A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)

A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies

Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels

A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor

Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study

A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma

A Registry for People With T-cell Lymphoma

Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors

A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors

A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

DS-3201b in Participants With Lymphomas

Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant

Other Conditions in Dallas